Back to Trials
NCT07572513NARecruitingAccepts Healthy Volunteers

Slowly Digestible Carbohydrates for GLP-1 Secretion

Purdue University

Start Date

5/1/2026

Completion Date

11/25/2026

Summary

The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in feelings of fullness and a decrease in hunger, and how long an elevated level of GLP-1 lasts after starch consumption. Researchers aim to address two questions: What amount of SDC maximizes GLP-1-mediated satiety, and does the impact to satiety continue in a second meal? The overall goal is to maximize ileal-digesting SDC's potential use as a food-based agent for weight loss. Researchers will compare 20, 40, and 60 g of raw corn starch compared to a maltodextrin control on total plasma GLP-1 concentrations, insulin, and blood glucose at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Researchers will also measure satiety at baseline, 60, 120, 180 minutes and after a second meal. There will be a total of 4 study visits with a least a 7-day break between visits. At each study visit, participants will: * Consume a randomized test beverage (SDC or maltodextrin) * Receive a blood draw at 7 timepoints over 3 hrs * Take a satiety questionnaire 5 times over 3 hrs * Consume a standardized lunch 3 hrs after the test beverage consumption

Eligibility Criteria

Age Range: 18 years to 45 years

Inclusion Criteria: 1. Healthy population 2. BMI between 18.5 and 24.9 kg/m2 3. Adults 18 - 45 years old 4. Men or women 5. Able to read/speak English 6. Fasting blood glucose levels ≤100 mg/dL 7. HbA1c ≤ 5.7% Exclusion Criteria: 1. Participants with 18 \> Years of Age \> 45 will be excluded. 2. Subjects with 18.5 kg/m² \> BMI \> 24.9 kg/m² will be excluded. 3. Diabetic individuals will be excluded. 4. Individuals with history of gastrointestinal disease will be excluded from the study. 5. Pregnant or nursing women will also be excluded. 6. Individuals taking GLP-1 medications, or on weight-loss diets or restrictive eating patterns. 7. Individuals suffering from dairy or gluten intolerance or allergies will be excluded.

Interventions

DIETARY_SUPPLEMENT

Maltodextrin (Placebo)

DIETARY_SUPPLEMENT

Raw Corn Starch

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Blood GlucoseGLP-1SatietySecond Meal IntakeHealthy Participant Study

Locations

Clinical Research Center at Purdue University

West Lafayette, Indiana 47907

United States